Altman Peter 4

What Happened Peter Altman, President & CEO and a director of BioCardia, purchased a total of 900 shares of BCDA stock in open-market transactions. He bought 600 shares on 2026-03-24 at a weighted average price of $1.24 (≈ $744) and 300 shares on 2026-03-25 at a weighted average price of $1.22 (≈ $366), for a combined cash outlay of about $1,110. These were purchases (code P) — acquisitions are generally more informative to investors than routine sales, though they do not prove intent.

Key Details

• Transaction dates and reported prices:
  • 2026-03-24: 600 shares at weighted avg $1.24 (footnote F1: actual trades ranged $1.24–$1.26)
  • 2026-03-25: 300 shares at weighted avg $1.22 (footnote F2: actual trades ranged $1.19–$1.25)
• Total shares acquired: 900; total reported value ≈ $1,110.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Filing timeliness: Report filed 2026-03-26 for trades on 3/24–3/25 — within the Form 4 reporting window (no late-filing indication).
• Transaction type: Open-market purchases (code P). Footnotes indicate each purchase was executed in multiple trades; weighted averages reported.

Context

• These are small, open-market purchases in dollar terms and should be seen as modest insider buying rather than a large commitment.
• No option exercises, gifts, or tax-withholding events are involved — just direct purchases.
• As always, factual insider purchases are one data point among many; they do not guarantee future stock performance.